Zentalis Pharmaceuticals, Inc. Restructuring and Related Cost, Incurred Cost
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Restructuring and Related Cost, Incurred Cost of $6.99 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostIncurredCost · last filed 2026-03-26
- Zentalis Pharmaceuticals, Inc. restructuring and related cost, incurred cost for the quarter ending 2025-12-31 was $0.00.
- Zentalis Pharmaceuticals, Inc. restructuring and related cost, incurred cost for the quarter ending 2025-09-30 was $0.00.
- Zentalis Pharmaceuticals, Inc. restructuring and related cost, incurred cost for the quarter ending 2025-06-30 was $0.00.
- Zentalis Pharmaceuticals, Inc. restructuring and related cost, incurred cost for the quarter ending 2025-03-31 was $6.99M.
- Zentalis Pharmaceuticals, Inc. restructuring and related cost, incurred cost for fiscal 2025 was $6.99M.
| Period end | Restructuring and Related Cost, Incurred Cost 3 month | Restructuring and Related Cost, Incurred Cost 6 month | Restructuring and Related Cost, Incurred Cost 9 month | Restructuring and Related Cost, Incurred Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | $6.99M 10-K · filed 2026-03-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $6.99M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $6.99M 10-Q · filed 2025-08-06 | ||
| 2025-03-31 | $6.99M 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |